Symbols / SVRA Stock $4.94 -3.89% Savara Inc.
SVRA (Stock) Chart
About
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Stock Fundamentals
Scroll to Statements| Market Cap | 1.01B | Enterprise Value | 1.10B | Income | -118.84M | Sales | — | Book/sh | 0.80 | Cash/sh | 0.93 |
| Dividend Yield | — | Payout | 0.00% | Employees | 70 | IPO | — | P/E | — | Forward P/E | -15.15 |
| PEG | — | P/S | — | P/B | 6.16 | P/C | — | EV/EBITDA | -8.93 | EV/Sales | — |
| Quick Ratio | 11.66 | Current Ratio | 11.85 | Debt/Eq | 14.73 | LT Debt/Eq | — | EPS (ttm) | -0.53 | EPS next Y | -0.33 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-05-13 | ROA | -32.91% | ROE | -63.45% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 204.66M | Shs Float | 130.03M | Short Float | 15.60% |
| Short Ratio | 15.04 | Short Interest | — | 52W High | 7.00 | 52W Low | 1.89 | Beta | 0.31 | Avg Volume | 1.60M |
| Volume | 379.69K | Target Price | $10.56 | Recom | Strong_buy | Prev Close | $5.14 | Price | $4.94 | Change | -3.89% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-23 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-12-18 | main | Wells Fargo | Overweight → Overweight | $9 |
| 2025-11-14 | main | Oppenheimer | Outperform → Outperform | $9 |
| 2025-11-13 | main | Citizens | Market Outperform → Market Outperform | $10 |
| 2025-10-23 | main | JMP Securities | Market Outperform → Market Outperform | $11 |
| 2025-09-09 | main | Guggenheim | Buy → Buy | $11 |
| 2025-09-08 | main | Oppenheimer | Outperform → Outperform | $8 |
| 2025-09-03 | main | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-08-15 | main | Oppenheimer | Outperform → Outperform | $6 |
| 2025-08-15 | up | HC Wainwright & Co. | Neutral → Buy | $5 |
| 2025-06-01 | main | Oppenheimer | Outperform → Outperform | $5 |
| 2025-05-29 | down | HC Wainwright & Co. | Buy → Neutral | $2 |
| 2025-05-28 | main | Evercore ISI Group | In-Line → In-Line | $2 |
| 2025-05-28 | main | Guggenheim | Buy → Buy | $8 |
| 2025-05-28 | main | Wells Fargo | Overweight → Overweight | $7 |
| 2025-03-31 | main | Evercore ISI Group | In-Line → Hold | $3 |
| 2025-03-28 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-12-20 | init | Wells Fargo | — → Overweight | $8 |
| 2024-12-19 | reit | JMP Securities | Market Outperform → Market Outperform | $9 |
| 2024-11-13 | main | HC Wainwright & Co. | Buy → Buy | $6 |
- Savara (SVRA) Stock: Pricing Efficiency Review | Q4 2025: EPS Misses Estimates - Low Growth - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 02
- SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN Mon, 20 Apr 2026 14
- Savara (NASDAQ:SVRA) Stock Price Up 2.5% - Here's Why - MarketBeat Sat, 18 Apr 2026 04
- Savara (SVRA) Stock: Why It Could Double (Mini Selloff) 2026-04-20 - Community Volume Signals - Xã Vĩnh Công Mon, 20 Apr 2026 15
- Savara Announces New Employment Inducement Grant - ChartMill Fri, 17 Apr 2026 20
- $SVRA stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Wed, 19 Nov 2025 08
- SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy - Stocktwits Wed, 15 Apr 2026 16
- Savara's rare lung disease drug gets 3 more months at FDA - Stock Titan Wed, 15 Apr 2026 20
- How Investors Are Reacting To Savara (SVRA) FDA Priority Review Extension For Molgramostim In Autoimmune PAP - simplywall.st Fri, 17 Apr 2026 12
- Savara gets FDA review extension for lead asset (SVRA:NASDAQ) - Seeking Alpha hu, 16 Apr 2026 10
- Savara (SVRA) Receives FDA Review Extension for Molgramostim App - GuruFocus hu, 16 Apr 2026 22
- Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat ue, 21 Apr 2026 08
- SVRA Stock Rises After Hours As FDA Grants Priority Review For Lung Disorder Therapy - Stocktwits Fri, 20 Feb 2026 23
- Savara brings new rare lung disease data to 3 ATS presentations - Stock Titan ue, 14 Apr 2026 12
- Rare lung disease drug enters accelerated U.K. review for Q4 decision - Stock Titan ue, 07 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
122.76
+19.89%
|
102.40
+72.94%
|
59.21
+55.64%
|
38.04
|
| Research And Development |
|
81.40
+4.33%
|
78.03
+76.29%
|
44.26
+58.76%
|
27.88
|
| Selling General And Administration |
|
42.06
+67.98%
|
25.04
+59.80%
|
15.67
+43.36%
|
10.93
|
| General And Administrative Expense |
|
42.06
+67.98%
|
25.04
+59.80%
|
15.67
+43.36%
|
10.93
|
| Other Gand A |
|
42.06
+67.98%
|
25.04
+59.80%
|
15.67
+43.36%
|
10.93
|
| Total Expenses |
|
122.76
+19.89%
|
102.40
+72.94%
|
59.21
+55.64%
|
38.04
|
| Operating Income |
|
-122.76
-19.89%
|
-102.40
-72.94%
|
-59.21
-55.64%
|
-38.04
|
| Total Operating Income As Reported |
|
-123.55
-19.72%
|
-103.20
-71.97%
|
-60.01
-54.50%
|
-38.84
|
| EBITDA |
|
-122.68
-19.95%
|
-102.27
-72.95%
|
-59.13
-56.12%
|
-37.88
|
| Normalized EBITDA |
|
-122.44
-19.66%
|
-102.32
-72.81%
|
-59.21
-56.40%
|
-37.86
|
| Reconciled Depreciation |
|
0.09
-33.08%
|
0.13
+68.83%
|
0.08
-53.89%
|
0.17
|
| EBIT |
|
-122.76
-19.89%
|
-102.40
-72.94%
|
-59.21
-55.64%
|
-38.04
|
| Total Unusual Items |
|
-0.24
-562.75%
|
0.05
-32.89%
|
0.08
+500.00%
|
-0.02
|
| Total Unusual Items Excluding Goodwill |
|
-0.24
-562.75%
|
0.05
-32.89%
|
0.08
+500.00%
|
-0.02
|
| Special Income Charges |
|
-0.55
|
0.00
|
—
|
—
|
| Other Special Charges |
|
0.55
|
—
|
—
|
—
|
| Net Income |
|
-118.84
-23.94%
|
-95.88
-75.29%
|
-54.70
-43.38%
|
-38.15
|
| Pretax Income |
|
-118.84
-23.94%
|
-95.88
-75.29%
|
-54.70
-43.38%
|
-38.15
|
| Net Non Operating Interest Income Expense |
|
4.16
-35.64%
|
6.47
+45.78%
|
4.44
+5140.91%
|
-0.09
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
0.09
|
| Net Interest Income |
|
4.16
-35.64%
|
6.47
+45.78%
|
4.44
+5140.91%
|
-0.09
|
| Interest Expense |
|
—
|
—
|
—
|
0.09
|
| Interest Income Non Operating |
|
4.16
-35.64%
|
6.47
+45.78%
|
4.44
|
—
|
| Interest Income |
|
4.16
-35.64%
|
6.47
+45.78%
|
4.44
|
—
|
| Other Income Expense |
|
-0.24
-562.75%
|
0.05
-32.89%
|
0.08
+500.00%
|
-0.02
|
| Gain On Sale Of Security |
|
0.31
+507.84%
|
0.05
-32.89%
|
0.08
+500.00%
|
-0.02
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-118.84
-23.94%
|
-95.88
-75.29%
|
-54.70
-43.38%
|
-38.15
|
| Net Income From Continuing Operation Net Minority Interest |
|
-118.84
-23.94%
|
-95.88
-75.29%
|
-54.70
-43.38%
|
-38.15
|
| Net Income From Continuing And Discontinued Operation |
|
-118.84
-23.94%
|
-95.88
-75.29%
|
-54.70
-43.38%
|
-38.15
|
| Net Income Continuous Operations |
|
-118.84
-23.94%
|
-95.88
-75.29%
|
-54.70
-43.38%
|
-38.15
|
| Normalized Income |
|
-118.60
-23.63%
|
-95.93
-75.14%
|
-54.77
-43.65%
|
-38.13
|
| Net Income Common Stockholders |
|
-118.84
-23.94%
|
-95.88
-75.29%
|
-54.70
-43.38%
|
-38.15
|
| Diluted EPS |
|
-0.53
-10.42%
|
-0.48
-45.45%
|
-0.33
-32.00%
|
-0.25
|
| Basic EPS |
|
-0.53
-10.42%
|
-0.48
-45.45%
|
-0.33
-32.00%
|
-0.25
|
| Basic Average Shares |
|
222.39
+12.21%
|
198.19
+19.97%
|
165.20
+8.14%
|
152.77
|
| Diluted Average Shares |
|
222.39
+12.21%
|
198.19
+19.97%
|
165.20
+8.14%
|
152.77
|
| Diluted NI Availto Com Stockholders |
|
-118.84
-23.94%
|
-95.88
-75.29%
|
-54.70
-43.38%
|
-38.15
|
| Depreciation Amortization Depletion Income Statement |
|
0.09
-33.08%
|
0.13
+68.83%
|
0.08
+148.39%
|
0.03
|
| Depreciation And Amortization In Income Statement |
|
0.09
-33.08%
|
0.13
+68.83%
|
0.08
+148.39%
|
0.03
|
| Other Taxes |
|
-0.78
+1.63%
|
-0.80
+0.00%
|
-0.80
-0.13%
|
-0.80
|
| Total Other Finance Cost |
|
—
|
—
|
-4.44
-5140.91%
|
0.09
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
253.44
+19.05%
|
212.88
+19.89%
|
177.56
+27.03%
|
139.78
|
| Current Assets |
|
241.62
+19.53%
|
202.13
+21.81%
|
165.95
+28.69%
|
128.95
|
| Cash Cash Equivalents And Short Term Investments |
|
235.70
+20.06%
|
196.33
+20.95%
|
162.32
+28.95%
|
125.88
|
| Cash And Cash Equivalents |
|
33.18
+119.33%
|
15.13
-43.10%
|
26.59
-48.97%
|
52.10
|
| Other Short Term Investments |
|
202.52
+11.77%
|
181.20
+33.50%
|
135.73
+83.98%
|
73.78
|
| Receivables |
|
1.25
+20.23%
|
1.04
+3.78%
|
1.00
+5.35%
|
0.95
|
| Taxes Receivable |
|
1.25
+20.23%
|
1.04
+3.78%
|
1.00
+5.35%
|
0.95
|
| Prepaid Assets |
|
3.37
-21.72%
|
4.31
+83.95%
|
2.34
+14.13%
|
2.05
|
| Hedging Assets Current |
|
0.39
|
0.00
|
—
|
—
|
| Other Current Assets |
|
0.89
+96.04%
|
0.46
+62.50%
|
0.28
+294.37%
|
0.07
|
| Total Non Current Assets |
|
11.82
+10.01%
|
10.74
-7.51%
|
11.62
+7.34%
|
10.82
|
| Net PPE |
|
0.10
-39.39%
|
0.17
-38.89%
|
0.27
+429.41%
|
0.05
|
| Gross PPE |
|
2.43
+4.56%
|
2.33
+1.97%
|
2.28
+15.60%
|
1.97
|
| Accumulated Depreciation |
|
-2.33
-7.91%
|
-2.16
-7.46%
|
-2.01
-4.63%
|
-1.92
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.12
+0.00%
|
0.12
+9.09%
|
0.11
+80.33%
|
0.06
|
| Other Properties |
|
1.98
+5.66%
|
1.87
+1.90%
|
1.84
+4.02%
|
1.77
|
| Leases |
|
0.33
+0.00%
|
0.33
+0.00%
|
0.33
+129.66%
|
0.14
|
| Other Intangible Assets |
|
11.64
+12.57%
|
10.34
-5.68%
|
10.96
+2.85%
|
10.66
|
| Other Non Current Assets |
|
0.08
-65.29%
|
0.24
-37.47%
|
0.39
+233.62%
|
0.12
|
| Total Liabilities Net Minority Interest |
|
50.30
+21.42%
|
41.43
+11.39%
|
37.19
+16.23%
|
32.00
|
| Current Liabilities |
|
20.40
+38.52%
|
14.72
+38.94%
|
10.60
+80.62%
|
5.87
|
| Payables And Accrued Expenses |
|
13.47
+40.50%
|
9.59
+49.67%
|
6.41
+86.39%
|
3.44
|
| Payables |
|
5.76
+26.67%
|
4.54
+29.71%
|
3.50
+162.67%
|
1.33
|
| Accounts Payable |
|
5.76
+26.67%
|
4.54
+29.71%
|
3.50
+162.67%
|
1.33
|
| Current Accrued Expenses |
|
7.72
+52.95%
|
5.05
+73.76%
|
2.90
+38.02%
|
2.10
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
6.55
+30.60%
|
5.02
+24.00%
|
4.05
+71.08%
|
2.37
|
| Current Debt And Capital Lease Obligation |
|
0.01
-93.97%
|
0.12
-18.88%
|
0.14
+123.44%
|
0.06
|
| Current Debt |
|
—
|
—
|
—
|
—
|
| Other Current Borrowings |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.01
-93.97%
|
0.12
-18.88%
|
0.14
+123.44%
|
0.06
|
| Other Current Liabilities |
|
0.36
|
—
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
29.91
+11.99%
|
26.71
+0.42%
|
26.59
+1.77%
|
26.13
|
| Long Term Debt And Capital Lease Obligation |
|
29.91
+12.35%
|
26.62
+1.03%
|
26.35
+1.04%
|
26.08
|
| Long Term Debt |
|
29.91
+12.35%
|
26.62
+1.03%
|
26.35
+1.04%
|
26.08
|
| Other Non Current Liabilities |
|
—
|
0.09
-64.78%
|
0.25
+357.41%
|
0.05
|
| Stockholders Equity |
|
203.13
+18.48%
|
171.45
+22.14%
|
140.37
+30.24%
|
107.78
|
| Common Stock Equity |
|
203.13
+18.48%
|
171.45
+22.14%
|
140.37
+30.24%
|
107.78
|
| Capital Stock |
|
0.20
+17.92%
|
0.17
+23.57%
|
0.14
+20.69%
|
0.12
|
| Common Stock |
|
0.20
+17.92%
|
0.17
+23.57%
|
0.14
+20.69%
|
0.12
|
| Share Issued |
|
204.57
+18.64%
|
172.42
+24.81%
|
138.14
+21.13%
|
114.05
|
| Ordinary Shares Number |
|
204.57
+18.64%
|
172.42
+24.81%
|
138.14
+21.13%
|
114.05
|
| Additional Paid In Capital |
|
811.10
+22.66%
|
661.28
+23.86%
|
533.87
+19.45%
|
446.94
|
| Retained Earnings |
|
-608.09
-24.29%
|
-489.25
-24.37%
|
-393.37
-16.15%
|
-338.67
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.09
+88.40%
|
-0.75
-176.75%
|
-0.27
+55.21%
|
-0.60
|
| Other Equity Adjustments |
|
-0.09
+88.40%
|
-0.75
-176.75%
|
-0.27
+55.21%
|
-0.60
|
| Total Equity Gross Minority Interest |
|
203.13
+18.48%
|
171.45
+22.14%
|
140.37
+30.24%
|
107.78
|
| Total Capitalization |
|
233.04
+17.66%
|
198.07
+18.80%
|
166.72
+24.55%
|
133.86
|
| Working Capital |
|
221.22
+18.04%
|
187.41
+20.64%
|
155.35
+26.21%
|
123.09
|
| Invested Capital |
|
233.04
+17.66%
|
198.07
+18.80%
|
166.72
+24.55%
|
133.86
|
| Total Debt |
|
29.91
+11.89%
|
26.73
+0.92%
|
26.49
+1.34%
|
26.14
|
| Net Debt |
|
—
|
11.49
|
—
|
—
|
| Capital Lease Obligations |
|
0.01
-93.97%
|
0.12
-18.88%
|
0.14
+123.44%
|
0.06
|
| Net Tangible Assets |
|
191.50
+18.86%
|
161.11
+24.50%
|
129.41
+33.25%
|
97.12
|
| Tangible Book Value |
|
191.50
+18.86%
|
161.11
+24.50%
|
129.41
+33.25%
|
97.12
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-101.04
-13.41%
|
-89.09
-74.47%
|
-51.06
-47.77%
|
-34.55
|
| Cash Flow From Continuing Operating Activities |
|
-101.04
-13.41%
|
-89.09
-74.47%
|
-51.06
-47.77%
|
-34.55
|
| Net Income From Continuing Operations |
|
-118.84
-23.94%
|
-95.88
-75.29%
|
-54.70
-43.38%
|
-38.15
|
| Depreciation Amortization Depletion |
|
0.09
-33.08%
|
0.13
+68.83%
|
0.08
-53.89%
|
0.17
|
| Depreciation |
|
—
|
—
|
0.17
+4.79%
|
0.17
|
| Depreciation And Amortization |
|
0.09
-33.08%
|
0.13
+68.83%
|
0.08
-53.89%
|
0.17
|
| Other Non Cash Items |
|
0.45
+67.16%
|
0.27
+0.00%
|
0.27
-18.86%
|
0.33
|
| Stock Based Compensation |
|
14.42
+46.26%
|
9.86
+136.00%
|
4.18
+104.70%
|
2.04
|
| Operating Gains Losses |
|
0.70
+385.52%
|
0.14
+559.09%
|
0.02
+15.79%
|
0.02
|
| Unrealized Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
0.00
+100.00%
|
-0.08
-500.00%
|
0.02
|
| Gain Loss On Sale Of PPE |
|
0.16
+8.97%
|
0.14
+47.96%
|
0.10
|
—
|
| Change In Working Capital |
|
5.00
+173.43%
|
1.83
-55.09%
|
4.07
+324.27%
|
0.96
|
| Change In Prepaid Assets |
|
0.10
+104.07%
|
-2.38
-422.59%
|
-0.46
-134.13%
|
1.34
|
| Change In Payables And Accrued Expense |
|
4.81
+14.40%
|
4.20
-7.49%
|
4.54
+1523.51%
|
-0.32
|
| Change In Payable |
|
4.81
+14.40%
|
4.20
-7.49%
|
4.54
+1523.51%
|
-0.32
|
| Change In Account Payable |
|
4.81
+14.40%
|
4.20
-7.49%
|
4.54
+1523.51%
|
-0.32
|
| Change In Other Current Assets |
|
0.10
+790.91%
|
0.01
+191.67%
|
-0.01
+78.95%
|
-0.06
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
0.00
|
| Investing Cash Flow |
|
-18.44
+53.83%
|
-39.94
+30.07%
|
-57.12
-208.49%
|
52.65
|
| Cash Flow From Continuing Investing Activities |
|
-18.44
+53.83%
|
-39.94
+30.07%
|
-57.12
-208.49%
|
52.65
|
| Net PPE Purchase And Sale |
|
-0.02
+12.00%
|
-0.03
+91.55%
|
-0.30
-3188.89%
|
-0.01
|
| Purchase Of PPE |
|
-0.02
+12.00%
|
-0.03
+91.55%
|
-0.30
-3188.89%
|
-0.01
|
| Capital Expenditure |
|
-0.02
+12.00%
|
-0.03
+91.55%
|
-0.30
-3188.89%
|
-0.01
|
| Net Investment Purchase And Sale |
|
-18.42
+53.86%
|
-39.92
+29.75%
|
-56.82
-207.91%
|
52.65
|
| Purchase Of Investment |
|
-204.90
+0.01%
|
-204.92
-5.51%
|
-194.22
-117.21%
|
-89.42
|
| Sale Of Investment |
|
186.48
+13.02%
|
165.00
+20.09%
|
137.40
-3.29%
|
142.07
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of Intangibles |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
137.81
+17.20%
|
117.58
+42.04%
|
82.78
+95049.43%
|
0.09
|
| Cash Flow From Continuing Financing Activities |
|
137.81
+17.20%
|
117.58
+42.04%
|
82.78
+95049.43%
|
0.09
|
| Net Issuance Payments Of Debt |
|
2.37
|
0.00
|
0.00
-100.00%
|
0.09
|
| Issuance Of Debt |
|
29.60
|
0.00
|
0.00
-100.00%
|
26.44
|
| Repayment Of Debt |
|
-27.23
|
0.00
|
0.00
+100.00%
|
-26.35
|
| Long Term Debt Issuance |
|
29.60
|
0.00
|
0.00
-100.00%
|
26.44
|
| Long Term Debt Payments |
|
-27.23
|
0.00
|
0.00
+100.00%
|
-26.35
|
| Net Long Term Debt Issuance |
|
2.37
|
0.00
|
0.00
-100.00%
|
0.09
|
| Net Common Stock Issuance |
|
135.09
+15.29%
|
117.18
+42.04%
|
82.50
+2750000.00%
|
-0.00
|
| Common Stock Payments |
|
-5.14
-416.58%
|
-0.99
+17.63%
|
-1.21
-40166.67%
|
-0.00
|
| Repurchase Of Capital Stock |
|
-5.14
-416.58%
|
-0.99
+17.63%
|
-1.21
-40166.67%
|
-0.00
|
| Proceeds From Stock Option Exercised |
|
0.35
-1.41%
|
0.35
+25.09%
|
0.28
+14050.00%
|
0.00
|
| Net Other Financing Charges |
|
—
|
0.05
|
—
|
—
|
| Changes In Cash |
|
18.33
+260.05%
|
-11.45
+54.91%
|
-25.40
-239.71%
|
18.18
|
| Effect Of Exchange Rate Changes |
|
-0.28
-5440.00%
|
-0.01
+95.76%
|
-0.12
-31.11%
|
-0.09
|
| Beginning Cash Position |
|
15.13
-43.10%
|
26.59
-48.97%
|
52.10
+53.18%
|
34.01
|
| End Cash Position |
|
33.18
+119.33%
|
15.13
-43.10%
|
26.59
-48.97%
|
52.10
|
| Free Cash Flow |
|
-101.06
-13.41%
|
-89.11
-73.52%
|
-51.36
-48.59%
|
-34.56
|
| Interest Paid Supplemental Data |
|
3.20
+50.71%
|
2.12
+4.12%
|
2.04
+26.39%
|
1.61
|
| Amortization Of Securities |
|
-2.87
+47.34%
|
-5.44
-9.19%
|
-4.98
-6745.33%
|
0.07
|
| Common Stock Issuance |
|
140.23
+18.66%
|
118.17
+41.18%
|
83.70
|
0.00
|
| Issuance Of Capital Stock |
|
140.23
+18.66%
|
118.17
+41.18%
|
83.70
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-20 View
- 8-K2026-03-13 View
- 10-K2026-03-13 View
- 42026-02-17 View
- 8-K2026-01-27 View
- 8-K2026-01-09 View
- 42025-12-19 View
- 42025-12-16 View
- 42025-12-16 View
- 42025-12-16 View
- 42025-12-16 View
- 42025-12-16 View
- 42025-12-11 View
- 42025-12-11 View
- 42025-12-11 View
- 42025-12-11 View
- 42025-12-11 View
- 42025-12-11 View
- 42025-12-04 View
- 42025-12-04 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|